Table 4.

Subgroup analysis for denosumab vs. bisphosphonates for risk of fracture

Subgroup	No. trials	P value	RR (95% CI)	I-squared
Drug of bisphosphonates
Alendronate	4	0.242	1.42 (0.79, 2.56)	0.00%
Risedronate	1	0.063	0.47 (0.21, 1.04)	_
Sample size of participants
No. (≤ 100 of participants)	3	0.434	1.53 (0.53, 4.45)	0.00%
No. (> 100 of participants)	2	0.605	0.87 (0.52, 1.46)	74.30%
Follow-up
= 12 months	3	0.313	1.39 (0.73, 2.66)	0.00%
= 24 months	2	0.229	0.66 (0.34, 1.30)	52.00%